A Phase 2 Study of HW211026 in Participants With Actinic Keratosis

NCT07513454 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Actinic Keratosis

Interventions

DRUG: HW211026
DRUG: HW211026

Sponsor

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.